Recombinant Human adenovirus C serotype 6 Early E3B 14.5 kDa protein

What is the primary function of the HAdV-C6 E3B 14.5 kDa protein in viral pathogenesis?

The E3B 14.5 kDa protein works in complex with the 10.4 kDa protein to modulate host immune responses. This protein complex is primarily involved in:

• Down-regulation of cell surface receptors including epidermal growth factor receptor (EGFR)

• Protection of infected cells from tumor necrosis factor (TNF)-mediated cytolysis

• Down-modulation of the apoptosis receptor CD95 (Fas, APO-1) on the cell surface

• Inhibition of Fas-mediated apoptosis in infected cells

This complex functions at the plasma membrane where it induces internalization and lysosomal degradation of target receptors, thereby helping the virus evade host immune surveillance .

How does the structural organization of E3B 14.5 kDa protein contribute to its function?

The E3B 14.5 kDa protein is an integral membrane protein containing specific sorting motifs in its cytoplasmic tail. Research has revealed:

• It contains YxxΦ sorting motifs that target proteins to endosomal/lysosomal compartments

• The protein is phosphorylated and O-glycosylated post-translationally

• It forms a physical complex with the 10.4 kDa protein, and both proteins exhibit mutual interdependence for cell surface expression

• Trafficking of the protein to the plasma membrane depends on concomitant expression of the 10.4 kDa protein

• Its membrane topology positions it to interact with cell surface targets like Fas and EGFR

What are the recommended methods for cloning and expressing recombinant HAdV-C6 E3B 14.5 kDa protein?

Based on recent protocols used for adenovirus genome modification, the following approach is recommended:

• Design of shuttle plasmids: Create a shuttle plasmid containing the E3B region with desired modifications

• In vitro recombination: Use in-fusion cloning techniques with appropriate restriction enzymes

• Expression verification: Employ Western blot analysis and immunoprecipitation with antibodies specific to the E3B 14.5 kDa protein

• Protein purification: Apply affinity chromatography techniques, often using His-tagged versions of the protein

For example, protocols have successfully utilized the In-Fusion HD cloning kit and Clone Amp HiFi PCR premix (Takara Bio) for recombination procedures and amplification steps. This approach allows selective modification of the E3B region without affecting the expression of neighboring genes .

What methods are most effective for detecting and measuring E3B 14.5 kDa protein expression?

For optimal results, combine these methods. For instance, researchers have effectively used immunoprecipitation followed by Western blot analysis to demonstrate the complex formation between 10.4 kDa and 14.5 kDa proteins .

How can the E3B 14.5 kDa gene be selectively mutated without affecting expression of neighboring genes?

Selective mutation of the E3B 14.5 kDa gene requires careful consideration of the E3 region's complex splicing patterns. Recommended approaches include:

• Minimal alterations: Use small insertions (1-4 bp) rather than large deletions to avoid disrupting splicing patterns

• Start codon mutation: Mutate the ATG start codon to prevent translation without altering mRNA splicing

• Frame-shift introduction: Create frame shifts that specifically disrupt the 14.5 kDa ORF

• Expression verification: Confirm that modifications affect only the target gene by assessing expression of neighboring genes (e.g., 10.4 kDa and 14.7 kDa proteins)

Research has shown that deletions within the E3 region can profoundly affect splicing, thereby increasing expression of some E3 proteins while severely reducing expression of others. For example, previous studies demonstrated that selective disruption of the 14.5 kDa ORF did not affect the expression level of E3 products encoded by neighboring E3 genes .

What is the significance of recombination in the E3 region, and how does it impact research on E3B 14.5 kDa protein?

The E3 region has been identified as a hotspot for recombination in adenovirus evolution. This has several implications for E3B 14.5 kDa protein research:

• Potential for natural variation in the protein sequence across different isolates

• Opportunities for creating novel variants through directed recombination

• Concerns regarding stability of E3-modified vectors over multiple passages

• Challenges in maintaining transgene integrity when inserted into the E3 region

A GC nucleotide content flux has been proposed as a potential marker for homologous recombination sites in adenoviruses, including within the E3 region. This is particularly important for researchers developing adenoviral vectors where transgenes are placed within the E3 cassette, as these might be susceptible to recombination during coinfection with wild-type adenoviruses .

How can researchers assess the immunomodulatory functions of recombinant E3B 14.5 kDa protein?

Several established assays can measure the immunomodulatory functions of E3B 14.5 kDa protein:

• CD95/Fas surface expression: Flow cytometry analysis of cells expressing E3B 14.5 kDa to quantify Fas down-regulation

• TNF sensitivity assays: Compare cell viability after TNF treatment between E3B 14.5 kDa-expressing cells and controls

• EGFR down-regulation assays: Measure EGFR levels by flow cytometry or Western blot in the presence/absence of 14.5 kDa protein

• Receptor trafficking studies: Track internalization of target receptors using fluorescence microscopy with specific inhibitors of endocytosis

• Apoptosis resistance measurements: Use annexin V/propidium iodide staining to assess protection from Fas-mediated apoptosis

Studies have shown that the 14.5 kDa protein requires the 10.4 kDa protein to form a functional complex. In experiments with selective gene disruptions, cells expressing mutant E3/14.5K genes showed restored cell surface Fas expression, demonstrating the protein's role in receptor down-regulation .

What protein-protein interactions are critical for E3B 14.5 kDa protein function, and how can they be studied?

Critical protein interactions and methods to study them include:

Research has established that the 10.4K-14.5K complex binds to Fas on the cell surface and induces its internalization into endosomes/lysosomes where it is degraded. This mechanism is consistent with the presence of YxxΦ sorting motifs in the cytoplasmic tail of 14.5K that target proteins to endosomal/lysosomal compartments .

How can HAdV-C6 E3B 14.5 kDa protein modifications enhance oncolytic virotherapy?

Recent research on HAdV-C6 as an oncolytic vector suggests several strategic modifications of the E3B 14.5 kDa protein:

• Selective replacement: Substituting the E3B 14.5 kDa coding region with therapeutic transgenes while preserving essential viral functions

• Immune modulation optimization: Fine-tuning the immunomodulatory functions to enhance anti-tumor immune responses

• Tissue-specific regulation: Placing the E3B 14.5 kDa under tumor-specific promoter control to restrict its expression to cancer cells

• Combination approaches: Using E3B modifications alongside other viral genomic changes (e.g., hTERT promoter control of E1A)

A promising approach demonstrated in recent studies involves insertion of the GM-CSF transgene to replace E3-6.7K/gp19K while leaving ADP and E3B region (including 14.5 kDa encoding sequences) intact. This modification was shown to significantly decrease tumor volume and improve survival time in murine models compared to mock-treated controls .

What are the challenges in developing species-specific assays for distinguishing HAdV-C6 E3B 14.5 kDa protein from other adenovirus serotypes?

Developing species-specific assays presents several challenges:

• Sequence homology: High conservation of the E3B 14.5 kDa protein sequences across adenovirus species C serotypes

• Cross-reactivity: Antibodies may recognize epitopes shared among different serotypes

• Functional redundancy: Similar immunomodulatory functions across serotypes despite sequence differences

• Interaction dependencies: Different requirements for complex formation with 10.4 kDa protein across serotypes

For precise identification, researchers can:

• Target unique epitopes using monoclonal antibodies against non-conserved regions

• Develop PCR primers spanning serotype-specific junctions

• Use proteomic approaches like mass spectrometry to identify signature peptides

• Apply comparative functional assays to detect subtle differences in receptor modulation

Research comparing species B and C adenoviruses has revealed differences in receptor usage and regulatory mechanisms, suggesting that species-specific characteristics can be exploited for differentiation despite high sequence conservation in some regions .

How does the E3B 14.5 kDa protein differ between HAdV-C6 and other human adenovirus species?

Comparative analysis reveals important differences between HAdV-C6 E3B 14.5 kDa protein and its counterparts in other adenovirus species:

These differences reflect evolutionary adaptations to distinct tissue tropisms and host immune pressures. The E3B 14.5 kDa protein in species C adenoviruses (including HAdV-C6) seems particularly adapted to modulate epithelial cell responses, consistent with their respiratory tract tropism .

What is the evidence for recombination events involving the E3B 14.5 kDa gene in adenovirus evolution?

Several lines of evidence support recombination involving the E3B 14.5 kDa gene:

• Genomic analyses: Complete genome sequences reveal mosaic patterns consistent with recombination events

• Proteotype analysis: Multiple unique proteotypes observed for some E3 proteins across different isolates

• Case studies: Identification of naturally occurring E3-deletion variants, such as the HAdV-7 GZ07 strain with 2864 bp deleted in the E3 region

• GC content fluctuation: Characteristic patterns of GC nucleotide content at recombination junctions

For example, the first reported case of E3 deletion in human adenovirus was the HAdV-7 GZ07 strain isolated from a child with acute respiratory disease. The deletion resulted in the loss of several E3 proteins while retaining only the left-end proteins (12.1 kDa glycoprotein and 16.1 kDa protein). This finding suggests that the E3 region, including the 14.5 kDa gene, is subject to natural recombination events that may contribute to adenovirus molecular evolution .

What methodological approaches can overcome the challenges in studying E3B 14.5 kDa protein interactions with host receptors?

Advanced methodological approaches include:

• Cryo-electron microscopy: For high-resolution structural determination of the 10.4K-14.5K complex with target receptors

• Bioluminescence resonance energy transfer (BRET): To study real-time protein interactions in living cells

• Proteomics-based interactome mapping: To identify the complete set of host proteins interacting with E3B 14.5 kDa

• CRISPR-Cas9 screening: To identify host factors required for 14.5 kDa protein function

• Super-resolution microscopy: To visualize trafficking of receptor complexes at nanoscale resolution

Research has demonstrated that direct binding studies (like Biacore analysis) combined with quantitative microscopy techniques such as Fluorescence Recovery After Photobleaching (FRAP) can effectively characterize protein-receptor interactions in adenovirus research. Similar approaches could be applied to study E3B 14.5 kDa protein interactions with its cellular targets .

How does the immunomodulatory function of E3B 14.5 kDa protein impact the design of HAdV-C6-based oncolytic virotherapies?

The immunomodulatory functions of E3B 14.5 kDa protein present both opportunities and challenges for oncolytic virotherapy:

Advantages to preserve/enhance function:

• Extended virus persistence in tumor microenvironment

• Reduced premature clearance by immune system

• Protection of infected tumor cells from TNF-mediated lysis

Advantages to delete/modify function:

• Enhanced immune recognition of infected tumor cells

• Potential for increased immunogenic cell death

• Opportunity to insert immunostimulatory transgenes

Optimization strategies often involve selective modification rather than complete deletion. For example, researchers have constructed a novel Ad6-hT-GM vector by inserting GM-CSF in place of E3-6.7K/gp19K while preserving other E3 functions. This approach resulted in enhanced anti-tumor effects against human breast cancer xenografts in murine models, significantly decreasing tumor volume and improving survival compared to controls .

What are the potential applications of recombinant E3B 14.5 kDa protein as a therapeutic immunomodulator independent of viral delivery?

The immunomodulatory properties of E3B 14.5 kDa protein suggest potential as a standalone therapeutic:

• Autoimmune disease management: Inhibition of Fas-mediated apoptosis could reduce tissue damage in autoimmune conditions

• Transplantation applications: Modulation of host immune responses to reduce rejection

• Inflammatory disease treatment: Down-regulation of TNF-mediated inflammation

• Cancer immunotherapy adjuvant: Strategic modulation of immune checkpoint pathways

• The 14.5 kDa protein requires complex formation with 10.4 kDa for activity

• Both proteins are membrane-associated, requiring appropriate delivery systems

• Potential immunogenicity of viral proteins when used as therapeutics

• Need for cell-type specific targeting to avoid systemic immunosuppression